About

Dikran Aivazian, Ph.D., is the Head of Research and Chief Technology Officer at ADAXION Therapeutics. As an experienced leader in drug discovery and an expert in biotherapeutics for autoimmune diseases and oncology, he leads both research and CMC at ADAXION. Dikran was a scientific co-founder of ADAXION and played a pivotal role in launching the company. Before ADAXION, he built and led the biotherapeutics discovery group at Inception Therapeutics, helping to launch several companies within the Inception/Versant Ventures portfolio.

Prior to his tenure at Inception, Dikran spent eight years at Pfizer, where he was a project leader and a biologics group lead at the Pfizer Centers for Therapeutic Innovation (CTI) and Biomedicines Design. Dikran started his industry career at Biogen Idec in 2006.

Dikran’s academic training was in immunology, biophysics, and cell biology. He earned his Bachelor of Science degree from the University of Toronto, completed his Ph.D. at the Massachusetts Institute of Technology (MIT), and conducted postdoctoral research at Stanford University.